These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 26751211)

  • 21. Unsolved Puzzles Surrounding HCV Immunity: Heterologous Immunity Adds Another Dimension.
    Agrawal B; Singh S; Gupta N; Li W; Vedi S; Kumar R
    Int J Mol Sci; 2017 Jul; 18(8):. PubMed ID: 28749434
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Priming with two DNA vaccines expressing hepatitis C virus NS3 protein targeting dendritic cells elicits superior heterologous protective potential in mice.
    Guan J; Deng Y; Chen H; Yin X; Yang Y; Tan W
    Arch Virol; 2015 Oct; 160(10):2517-24. PubMed ID: 26215441
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Multiantigenic DNA Vaccine That Induces Broad Hepatitis C Virus-Specific T-Cell Responses in Mice.
    Gummow J; Li Y; Yu W; Garrod T; Wijesundara D; Brennan AJ; Mullick R; Voskoboinik I; Grubor-Bauk B; Gowans EJ
    J Virol; 2015 Aug; 89(15):7991-8002. PubMed ID: 26018154
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enhanced T cell responses against hepatitis C virus by ex vivo targeting of adenoviral particles to dendritic cells.
    Echeverria I; Pereboev A; Silva L; Zabaleta A; Riezu-Boj JI; Bes M; Cubero M; Borras-Cuesta F; Lasarte JJ; Esteban JI; Prieto J; Sarobe P
    Hepatology; 2011 Jul; 54(1):28-37. PubMed ID: 21452282
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Induction of humoural and cellular immunity by immunisation with HCV particle vaccine in a non-human primate model.
    Yokokawa H; Higashino A; Suzuki S; Moriyama M; Nakamura N; Suzuki T; Suzuki R; Ishii K; Kobiyama K; Ishii KJ; Wakita T; Akari H; Kato T
    Gut; 2018 Feb; 67(2):372-379. PubMed ID: 27797937
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term humoral and cellular immunity induced by a single immunization with replication-defective adenovirus recombinant vector.
    Juillard V; Villefroy P; Godfrin D; Pavirani A; Venet A; Guillet JG
    Eur J Immunol; 1995 Dec; 25(12):3467-73. PubMed ID: 8566039
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Induction of primary human T cell responses against hepatitis C virus-derived antigens NS3 or core by autologous dendritic cells expressing hepatitis C virus antigens: potential for vaccine and immunotherapy.
    Li W; Krishnadas DK; Li J; Tyrrell DL; Agrawal B
    J Immunol; 2006 May; 176(10):6065-75. PubMed ID: 16670315
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of a heterologous, multigenotype vaccine against hepatitis C virus infection.
    Encke J; Radunz W; Eisenbach C; Geib J; Gehrke S; Pfaff E; Stremmel W
    Eur J Clin Invest; 2007 May; 37(5):396-406. PubMed ID: 17461986
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunogenicity of heterologous recombinant adenovirus prime-boost vaccine regimens is enhanced by circumventing vector cross-reactivity.
    Thorner AR; Lemckert AA; Goudsmit J; Lynch DM; Ewald BA; Denholtz M; Havenga MJ; Barouch DH
    J Virol; 2006 Dec; 80(24):12009-16. PubMed ID: 17035318
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficient immunization of rhesus macaques with an HCV candidate vaccine by heterologous priming-boosting with novel adenoviral vectors based on different serotypes.
    Fattori E; Zampaglione I; Arcuri M; Meola A; Ercole BB; Cirillo A; Folgori A; Bett A; Cappelletti M; Sporeno E; Cortese R; Nicosia A; Colloca S
    Gene Ther; 2006 Jul; 13(14):1088-96. PubMed ID: 16554842
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Immunogenicity and heterologous protection in mice with a recombinant adenoviral-based vaccine carrying a hepatitis C virus truncated NS3 and core fusion protein].
    Guan J; Deng Y; Chen H; Yang Y; Wen B; Tan W
    Bing Du Xue Bao; 2015 Jan; 31(1):7-13. PubMed ID: 25997323
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Live and killed rhabdovirus-based vectors as potential hepatitis C vaccines.
    Siler CA; McGettigan JP; Dietzschold B; Herrine SK; Dubuisson J; Pomerantz RJ; Schnell MJ
    Virology; 2002 Jan; 292(1):24-34. PubMed ID: 11878905
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Experimental study of immunization of mice with hepatitis C virus genetic vaccine constructs].
    Dou J; Liu K; Chen Z; Wo J; Liu Y; Xu C; Chen M; Jin J; He N
    Zhonghua Nei Ke Za Zhi; 1999 Jun; 38(6):390-2. PubMed ID: 11798674
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Induction of multispecific Th-1 type immune response against HCV in mice by protein immunization using CpG and Montanide ISA 720 as adjuvants.
    Qiu Q; Wang RY; Jiao X; Jin B; Sugauchi F; Grandinetti T; Alter HJ; Shih JW
    Vaccine; 2008 Oct; 26(43):5527-5534. PubMed ID: 18675871
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Coupling to the surface of liposomes alters the immunogenicity of hepatitis C virus-derived peptides and confers sterile immunity.
    Takagi A; Kobayashi N; Taneichi M; Uchida T; Akatsuka T
    Biochem Biophys Res Commun; 2013 Jan; 430(1):183-9. PubMed ID: 23159619
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Induction of antigen-specific immune responses in vivo after vaccination with dendritic cells transduced with adenoviral vectors encoding hepatitis C virus NS3.
    Xiang M; Eisenbach C; Lupu CM; Ernst E; Stremmel W; Encke J
    Viral Immunol; 2006; 19(2):210-9. PubMed ID: 16817764
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity.
    Lemckert AA; Sumida SM; Holterman L; Vogels R; Truitt DM; Lynch DM; Nanda A; Ewald BA; Gorgone DA; Lifton MA; Goudsmit J; Havenga MJ; Barouch DH
    J Virol; 2005 Aug; 79(15):9694-701. PubMed ID: 16014931
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effective induction of type 1 cytotoxic T cell responses in mice with DNA vaccine encoding two hepatitis C virus cytotoxic T lymphocyte epitopes.
    Shi L; Liu S; Fan GX; Sheng L; Ren HX; Yuan YK
    Viral Immunol; 2006; 19(4):702-11. PubMed ID: 17201665
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preclinical evaluation of multi antigenic HCV DNA vaccine for the prevention of Hepatitis C virus infection.
    Lee H; Jeong M; Oh J; Cho Y; Shen X; Stone J; Yan J; Rothkopf Z; Khan AS; Cho BM; Park YK; Weiner DB; Son WC; Maslow JN
    Sci Rep; 2017 Mar; 7():43531. PubMed ID: 28266565
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Different doses of adenoviral vector expressing IL-12 enhance or depress the immune response to a coadministered antigen: the role of nitric oxide.
    Lasarte JJ; Corrales FJ; Casares N; López-Díaz de Cerio A; Qian C; Xie X; Borrás-Cuesta F; Prieto J
    J Immunol; 1999 May; 162(9):5270-7. PubMed ID: 10228002
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.